Clinical Trials Logo

Clinical Trial Summary

Vitamin A deficiency (VAD) increases the risk of death from infections in infants and young children. The World Health Organization (WHO) recommends high-dose vitamin A supplementation (VAS) from 6-59 months of age to reduce the risk of death in countries where VAD is common. Such countries include Bangladesh, where this study is being conducted. While providing VAS at 6 months is recommended, providing VAS at birth may also decrease the risk of death since newborn infants are also at risk of VAD. VAS presumably reduces infant mortality by improving the immune response to infection and immunization. Vitamin A particularly affects the development and function of T cells, which develop in the thymus and are a key component of the memory response to infection and immunization. Vitamin A is important for development of an important class of T cells, regulatory T-cells, in the intestine. Regulatory T-cells prevent over-reaction of the immune system to substances the immune system might otherwise treat as harmful such as food or the healthy bacteria in the intestine. VAD could disrupt the normal colonization of the infant's intestinal tract and cause a condition called "dysbiosis" where abnormal bacteria flourish and adversely affect the infant's immune system. Dysbiosis may disrupt the immune response to injectable and oral vaccines. VAS at birth may prevent dysbiosis and thus improve immune function, response to vaccines, and child survival. The investigators recently completed an intervention trial in Bangladeshi infants (NCT01583972) examining the effect of VAS at birth on immune function and response to vaccines administered from birth to 14 wk of age. The present study will recruit infants who completed NCT01583972 when they are from 12 to 24 m of age to determine if VAS at birth affects the responses to these same vaccines when they are measured during the second year of life. The investigators will examine the effect of VAS at birth on gut microbiota measured early in infancy and during the second year of life, and explore the association of the gut microbiota with vaccine response. Mothers of study infants will participate in the study because the breast milk oligosaccharide content strongly affects gut microbiota composition and the "secretor status" of the mother, which can be determined from maternal FUT2 genotype, strongly affects breast milk oligosaccharide content.


Clinical Trial Description

Hypotheses and Specific Aims The investigators will test the hypotheses that VAS at birth will (1) improve production of new T cells at 1-2 yr of age; (2) improve T-cell memory responses at 1-2 yr of age to vaccines given early in infancy (birth - 14 wk); and (3) alter intestinal colonization early in infancy (6, 11 and 15 wk) and at 1-2 yr of age to increase Bifidobacterium and other healthy bacteria and decrease Proteobacteria and other harmful bacteria. Because the "secretor status" of the mother affects the carbohydrate content of the breastmilk, which can in turn affect Bifidobacterium growth in the infant gut, the "secretor status" of the mother will be determined. Furthermore these differences in composition of the intestinal bacteria will be associated with greater immunologic responses to oral and systemic vaccines.

Specific Aim 1: Determine if VAS or placebo at birth affect the blood concentration and thymic output of naïve T-cells at 1-2 yr of age. Specific Aim 2: Determine if VAS or placebo at birth affect T-cell mediated responses at 1-2 yr of age to vaccines given early in infancy, including serum and intestinal antibody levels, vaccine-specific proliferative responses by T cells and cytokine production by T cells. Specific Aim 3: Determine if VAS or placebo at birth affect the relative abundance of healthy intestinal bacteria and common harmful bacteria in the feces at 6, 11, and 15 wk of age and at 1-2 yr of age and determine if relative abundance of these bacteria correlates with vaccine responses shortly after vaccination (6, 11, 15 wk) and later in infancy (1-2 yr). As part of Aim 3 the "secretor status" genotype (FUT2 gene) of the mother will be determined from a cheek swab DNA sample. ;


Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT02027610
Study type Observational
Source USDA, Western Human Nutrition Research Center
Contact
Status Completed
Phase N/A
Start date October 2014
Completion date September 2015

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03353662 - Sub Regional Micronutrient Survey in Ethiopia
Completed NCT01061307 - An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand Phase 0
Completed NCT00082420 - Retinol Equivalence of Plant Carotenoids in Children N/A
Completed NCT03383744 - Using Stable Isotopes to Assess the Effectiveness of Vitamin A Supplementation in Cameroon N/A
Recruiting NCT04438200 - Liver and Bone Retinol Levels in Guatemalan Adolescents and Adults
Not yet recruiting NCT06450925 - Vitamin A Supplementation in Allogeneic Stem Cell Transplantation. N/A
Completed NCT02996513 - Assessing Model Parameters for Applying the Retinol Isotope Dilution (RID) Method N/A
Completed NCT01922713 - Effect of Daily Consumption of Orange Maize on Breast Milk Retinol in Lactating Zambian Women N/A
Completed NCT02043223 - Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit Phase 2/Phase 3
Completed NCT05882682 - Impact of Food-to-Food Fortified Cereal Products on Diet Quality in Eldoret, Kenya
Completed NCT04632771 - Nutritional Status and Bouillon Use in Northern Ghana
Completed NCT02760095 - Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
Active, not recruiting NCT01476358 - Effect of Vitamin A Supplementation on Immune Responses in Human Neonates Phase 2
Completed NCT04137354 - Iron and Vitamin A in School Children N/A
Completed NCT00198718 - Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates Phase 2
Not yet recruiting NCT04127968 - Efficacy and Safety of Vitamin A Treatment for Children With Sepsis N/A
Completed NCT03640104 - Individualized Dietary Intervention in Breastfeeding Women: Body Weight and Vitamin A Stores N/A
Completed NCT01614483 - Efficacy of Yellow Cassava to Improve Vitamin A Status of Kenyan School Children N/A
Completed NCT02804490 - Efficacy of Biofortified Maize to Improve Maternal and Infant Vitamin A Status Phase 3
Completed NCT02702622 - Vitamin A Equivalence of the Provitamin A in Biofortified Bananas N/A